An Open-Label Study to Evaluate the Safety and Tolerability of BTX 1503 Solution in Patients with Acne Vulgaris
Latest Information Update: 18 Apr 2022
At a glance
- Drugs Cannabidiol (Primary)
- Indications Acne vulgaris
- Focus Adverse reactions
- Sponsors Botanix Pharmaceuticals
- 14 Feb 2018 Status changed from not yet recruiting to completed.
- 03 Oct 2017 Planned initiation date changed from 10 Aug 2017 to 10 Oct 2017.
- 02 Aug 2017 New trial record